Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has provided an update.
Hansoh Pharmaceutical Group Company Limited has announced that its self-developed innovative drug, HS-10542 capsules, has received Clinical Trial Approval from China’s National Medical Products Administration. This approval allows the company to conduct clinical trials for the treatment of paroxysmal nocturnal hemoglobinuria and immunoglobulin A nephropathy, potentially strengthening its position in the pharmaceutical industry and offering new treatment options for these conditions.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative drugs. The company operates in the healthcare industry, with a market focus on creating treatments for various medical conditions.
Average Trading Volume: 12,089,628
Technical Sentiment Signal: Buy
Current Market Cap: HK$157.9B
For detailed information about 3692 stock, go to TipRanks’ Stock Analysis page.